EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antibodies and α-synuclein: What to target against Parkinson's Disease?

Daniel E Otzen

Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · 2024-02 · 1872 (2) · 140943

DOI: 10.1016/j.bbapap.2023.140943 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2024-02. Verfasst von Daniel E Otzen. Beteiligte Einrichtung: Interdisciplinary Nanoscience Centre (iNANO), Department of Molecular Biology and Genetics, Aarhus University, Gustav Wieds Vej 14, DK - 8000, Aarhus…. Hauptthemen laut MEDLINE: Parkinson Disease, Intrinsically Disordered Proteins. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lundbeck Foundation, Independent Research Fund Denmark, Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson's Disease (PD) is strongly linked to the aggregation of the protein α-synuclein (α-syn), an intrinsically disordered protein. However, strategies to combat PD by targeting the aggregation of α-syn are challenged by the multiple types of aggregates formed both in vivo and in vitro, the potential influence of chemical modifications and the as yet unresolved question of which aggregate types (oligomeric or fibrillar) are most cytotoxic. Here I briefly review the social history of α-syn, the many efforts to raise antibodies against α-syn and the disappointing results of clinical trials based on such antibodies. Ultimately a thorough understanding of the molecular and mechanistic properties of mAbs towards aggregated species of α-syn is an essential prerequisite for any clinical trial, but this is missing in most cases. I highlight new microfluidic techniques which may address this need and call for a more concerted effort to standardize antibody studies as the basis to allow us to link molecular insights to clinical efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseIntrinsically Disordered ProteinsHumansalpha-SynucleinProtein AggregatesAntibodies, Monoclonal

Stichwörter der Autor:innen

AntibodiesMicrofluidicsOligomers, fibrilsParkinson's diseaseα-Synuclein

Substanzen

alpha-SynucleinProtein AggregatesAntibodies, MonoclonalIntrinsically Disordered Proteins

Autor:innen und Institutionen

  • Interdisciplinary Nanoscience Centre (iNANO), Department of Molecular Biology and Genetics, Aarhus University, Gustav Wieds Vej 14, DK - 8000, Aarhus, Denmark. Electronic address: dao@inano.au.dk.

Förderung

  • Lundbeck Foundation
  • Independent Research Fund Denmark
  • Novo Nordisk Fonden

Zitieren

APA

Otzen, D. E. (2024). Antibodies and α-synuclein: What to target against Parkinson's Disease?. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1872(2), 140943. https://doi.org/10.1016/j.bbapap.2023.140943

Vancouver

Otzen DE. Antibodies and α-synuclein: What to target against Parkinson's Disease?. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 2024;1872(2):140943. doi:10.1016/j.bbapap.2023.140943

BibTeX
@article{Otzen2024,
  author = {Otzen, Daniel E},
  title = {Antibodies and α-synuclein: What to target against Parkinson's Disease?},
  journal = {Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics},
  year = {2024},
  volume = {1872},
  number = {2},
  pages = {140943},
  doi = {10.1016/j.bbapap.2023.140943}
}
Kostenlos starten →